文献速递胸部肿瘤

晚期鳞状细胞肺癌EGFR单抗疗效预测生物标志物

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

本文综述了晚期非小细胞肺癌(含鳞状细胞肺癌)中EGFR靶向单抗联合治疗的疗效预测生物标志物。III期临床试验数据显示,肿瘤EGFR蛋白高表达(H-score≥200)和/或EGFR基因拷贝数增加的患者从EGFR单抗联合化疗中获益更大。然而,EGFR单抗联合免疫治疗或抗血管生成治疗的生物标志物数据有限或缺失。

要点

  • EGFR蛋白高表达(H-score≥200)或基因拷贝数增加可预测EGFR单抗联合化疗的获益。
  • EGFR单抗联合免疫治疗或抗血管生成治疗的生物标志物数据有限或缺失。
  • 需进一步验证上述标志物以筛选从EGFR单抗治疗中获益最大的患者。

核心结论

  • EGFR单抗联合化疗在EGFR蛋白高表达和/或基因拷贝数增加的NSCLC(含SqCLC)患者中临床获益更大。
  • 支持验证这些标志物以识别从EGFR单抗治疗中获益最大的患者。
  • EGFR单抗联合免疫或抗血管生成治疗的生物标志物数据仍有限。

研究设计与样本

  • 检索文献中EGFR靶向单抗(西妥昔单抗和奈妥木单抗)联合化疗、免疫治疗或抗血管生成治疗晚期NSCLC(含SqCLC)的随机试验。
  • 总结潜在生物标志物与结局的关联结果。

主要发现

  • III期临床试验数据表明,肿瘤EGFR蛋白高表达(H-score≥200)和/或EGFR基因拷贝数增加(如FISH检测≥40%细胞有≥4个EGFR拷贝;≥10%分析细胞有基因扩增)的患者从EGFR单抗治疗中获益更大。
  • EGFR单抗联合免疫治疗的生物标志物数据有限。
  • EGFR单抗联合抗血管生成治疗的生物标志物数据缺失。

关键数值与推荐

  • EGFR蛋白高表达定义为H-score≥200。
  • EGFR基因拷贝数增加定义为FISH检测≥40%细胞有≥4个EGFR拷贝或≥10%分析细胞有基因扩增。

临床怎么用

  • 对于晚期鳞状细胞肺癌患者,可考虑检测EGFR蛋白表达和基因拷贝数以筛选可能从EGFR单抗联合化疗中获益的人群。
  • EGFR单抗联合免疫或抗血管生成治疗时,生物标志物指导选择证据不足。

局限性

  • EGFR单抗联合免疫治疗和抗血管生成治疗的生物标志物数据有限或缺失。
  • 本文为综述,未报告新的前瞻性研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer (SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy number, EGFR mutation, and EGFR protein expression as biomarkers can help select patients who respond to treatment, it is important to consider biomarkers for response in patients treated with combination therapies that include EGFR mAbs. DESIGN: Randomized trials of EGFR-directed mAbs cetuximab and necitumumab in combination with chemotherapy, immunotherapy, or antiangiogenic therapy in patients with advanced NSCLC, including SqCLC, were searched in the literature. Results of associations of potential biomarkers and outcomes were summarized. RESULTS: Data from phase III clinical trials indicate that patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein (H-score of ≥200) and/or gene copy numbers of EGFR (e.g. ≥40% cells with ≥4 EGFR copies as detected by fluorescence in situ hybridization; gene amplification in ≥10% of analyzed cells) derive greater therapeutic benefits from EGFR-directed mAbs. Biomarker data are limited for EGFR mAbs used in combination with immunotherapy and are absent when used in combination with antiangiogenic agents. CONCLUSIONS: Therapy with EGFR-directed mAbs in combination with chemotherapy is associated with greater clinical benefits in patients with NSCLC, including SqCLC, whose tumors express high levels of EGFR protein and/or have increased EGFR gene copy number. These data support validating the role of these as biomarkers to identify those patients who derive the greatest clinical benefit from EGFR mAb therapy. However, data on biomarkers for EGFR-directed mAbs combined with immunotherapy or antiangiogenic agents remain limited.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bonomi PD, Gandara D, Hirsch FR, et al. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer. Ann Oncol. 2018. PMID: 29905778. doi:10.1093/annonc/mdy196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。